secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001517022-24-000070
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access
--------------------------------------------------------------------------------

- Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.
- Vafseo (vadadustat) expected to be available in the U.S. in January 2025.
- CMS granted TDAPA reimbursement for Vafseo starting January 1, 2025, and issued a HCPCS billing code.
- Vafseo received FDA approval in March 2024 for anemia due to CKD in adults on dialysis for at least 3 months.
- Agreement enables physicians to prescribe Vafseo as clinically appropriate; commercial launch priority.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000070/0001517022-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000070/akba-20241022.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer